Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Real World Study on the Effect of Single or Combined Treatment of Anlotinib on Survival and Prognosis of Advanced Hepatocellular Carcinoma

NCT04954521 is registered in ClinicalTrials.gov with People's Hospital of Guangxi Zhuang Autonomous Region as lead sponsor.

NCT NCT04954521
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04954521 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Real World Study on the Effect of Single or Combined Treatment of Anlotinib on Survival and Prognosis of Advanced Hepatocellular Carcinoma
Lead sponsor
People's Hospital of Guangxi Zhuang Autonomous Region
Phase
Observational
Overall status
Unknown status
Start date
June 30, 2021
Completion date
July 5, 2024
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

liver neoplasms